These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34851425)

  • 21. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of dexmedetomidine combined with therapeutic hypothermia in a piglet asphyxia model.
    Ezzati M; Broad K; Kawano G; Faulkner S; Hassell J; Fleiss B; Gressens P; Fierens I; Rostami J; Maze M; Sleigh JW; Anderson B; Sanders RD; Robertson NJ
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):733-42. PubMed ID: 24724965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanism-based population pharmacokinetic and pharmacodynamic modeling of intravenous and intranasal dexmedetomidine in healthy subjects.
    Yoo H; Iirola T; Vilo S; Manner T; Aantaa R; Lahtinen M; Scheinin M; Olkkola KT; Jusko WJ
    Eur J Clin Pharmacol; 2015 Oct; 71(10):1197-207. PubMed ID: 26233335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics meta-analysis of plitidepsin (Aplidin) in cancer subjects.
    Nalda-Molina R; Valenzuela B; Ramon-Lopez A; Miguel-Lillo B; Soto-Matos A; Perez-Ruixo JJ
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):97-108. PubMed ID: 18941750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration.
    Ashraf MW; Uusalo P; Scheinin M; Saari TI
    Clin Pharmacokinet; 2020 Nov; 59(11):1467-1482. PubMed ID: 32462542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of dexmedetomidine on the minimum alveolar concentration of isoflurane in cats.
    Escobar A; Pypendop BH; Siao KT; Stanley SD; Ilkiw JE
    J Vet Pharmacol Ther; 2012 Apr; 35(2):163-8. PubMed ID: 21521237
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of target controlled infusion to derive age and gender covariates for propofol clearance.
    White M; Kenny GN; Schraag S
    Clin Pharmacokinet; 2008; 47(2):119-27. PubMed ID: 18193918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fixed dosing of intravenous tocilizumab in rheumatoid arthritis. Results from a population pharmacokinetic analysis.
    Bastida C; Ruiz-Esquide V; Pascal M; de Vries Schultink AHM; Yagüe J; Sanmartí R; Huitema ADR; Soy D
    Br J Clin Pharmacol; 2018 Apr; 84(4):716-725. PubMed ID: 29314183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of pharmacokinetic models of intravenous dexmedetomidine in sedated patients under spinal anesthesia.
    Obara S; Imaizumi T; Hakozaki T; Hosono A; Iseki Y; Sanbe N; Murakawa M
    J Anesth; 2018 Feb; 32(1):33-40. PubMed ID: 29098392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans.
    Angst MS; Ramaswamy B; Davies MF; Maze M
    Anesthesiology; 2004 Sep; 101(3):744-52. PubMed ID: 15329600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic Interaction of Remifentanil and Dexmedetomidine on Depth of Sedation and Tolerance of Laryngoscopy.
    Weerink MAS; Barends CRM; Muskiet ERR; Reyntjens KMEM; Knotnerus FH; Oostra M; van Bocxlaer JFP; Struys MMRF; Colin PJ
    Anesthesiology; 2019 Nov; 131(5):1004-1017. PubMed ID: 31425170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous paracetamol (propacetamol) pharmacokinetics in term and preterm neonates.
    Allegaert K; Anderson BJ; Naulaers G; de Hoon J; Verbesselt R; Debeer A; Devlieger H; Tibboel D
    Eur J Clin Pharmacol; 2004 May; 60(3):191-7. PubMed ID: 15071761
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children.
    Liu HC; Lian QQ; Wu FF; Wang CY; Sun W; Zheng LD; Schüttler J; Ihmsen H
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):201-211. PubMed ID: 27037817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
    Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
    Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.
    Hennig S; Norris R; Kirkpatrick CM
    Br J Clin Pharmacol; 2008 Apr; 65(4):502-10. PubMed ID: 17995972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Pharmacokinetic and Pharmacodynamic Study of Oral Dexmedetomidine.
    Chamadia S; Pedemonte JC; Hobbs LE; Deng H; Nguyen S; Cortinez LI; Akeju O
    Anesthesiology; 2020 Dec; 133(6):1223-1233. PubMed ID: 32986820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of PM00104 (Zalypsis(®)) in cancer patients.
    Pérez-Ruixo C; Valenzuela B; Fernández Teruel C; González-Sales M; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):15-24. PubMed ID: 21590449
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Aztreonam Dosing Regimens in Patients With Normal and Impaired Renal Function: A Population Pharmacokinetic Modeling and Monte Carlo Simulation Analysis.
    Xu H; Zhou W; Zhou D; Li J; Al-Huniti N
    J Clin Pharmacol; 2017 Mar; 57(3):336-344. PubMed ID: 27530649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.